Cargando…
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019
This analysis is the largest population‐based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD‐O‐3) coded Langerhans cell histiocytosis (LCH) from England. People of all ages were...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826274/ https://www.ncbi.nlm.nih.gov/pubmed/36122574 http://dx.doi.org/10.1111/bjh.18459 |
_version_ | 1784866811638972416 |
---|---|
author | Liu, Hanhua Stiller, Charles A. Crooks, Colin J. Rous, Brian Bythell, Mary Broggio, John Rankin, Judith Nanduri, Vasanta Lanyon, Peter Card, Tim R. Ban, Lu Elliss‐Brookes, Lucy Broughan, Jennifer M. Paley, Lizz Wong, Kwok Bacon, Andrew Bishton, Mark West, Joe |
author_facet | Liu, Hanhua Stiller, Charles A. Crooks, Colin J. Rous, Brian Bythell, Mary Broggio, John Rankin, Judith Nanduri, Vasanta Lanyon, Peter Card, Tim R. Ban, Lu Elliss‐Brookes, Lucy Broughan, Jennifer M. Paley, Lizz Wong, Kwok Bacon, Andrew Bishton, Mark West, Joe |
author_sort | Liu, Hanhua |
collection | PubMed |
description | This analysis is the largest population‐based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD‐O‐3) coded Langerhans cell histiocytosis (LCH) from England. People of all ages were identified from the National Cancer Registration Dataset using ICD‐O‐3 morphologies 9751–9754 for neoplasms diagnosed in 2013–2019. A total of 658 patients were identified, of whom 324 (49%) were children aged <15 years. The age‐standardised incidence rate was 4.46 (95% confidence interval [CI] 3.99–4.98) per million children and 1.06 (95% CI 0.94–1.18) per million adults aged ≥15 years. Prevalence of LCH was 9.95 (95% CI 9.14–10.81) per million persons at the end of 2019. The 1‐year overall survival (OS) was 99% (95% CI 97%–100%) for children and 90% (95% CI 87%–93%) for adults. Those aged ≥60 years had poorer OS than those aged <15 years (hazard ratio [HR] 22.12, 95% CI 7.10–68.94; p < 0.001). People in deprived areas had lower OS than those in the least deprived areas (HR 5.36, 95% CI 1.16–24.87; p = 0.03). There will inevitably be other environmental factors and associations yet to be identified, and the continued standardised data collection will allow further evaluation of data over time. This will be increasingly important with developments in LCH management following the large collaborative international trials such as LCH IV. |
format | Online Article Text |
id | pubmed-9826274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98262742023-01-09 Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 Liu, Hanhua Stiller, Charles A. Crooks, Colin J. Rous, Brian Bythell, Mary Broggio, John Rankin, Judith Nanduri, Vasanta Lanyon, Peter Card, Tim R. Ban, Lu Elliss‐Brookes, Lucy Broughan, Jennifer M. Paley, Lizz Wong, Kwok Bacon, Andrew Bishton, Mark West, Joe Br J Haematol Haematological Malignancy‐clinical This analysis is the largest population‐based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD‐O‐3) coded Langerhans cell histiocytosis (LCH) from England. People of all ages were identified from the National Cancer Registration Dataset using ICD‐O‐3 morphologies 9751–9754 for neoplasms diagnosed in 2013–2019. A total of 658 patients were identified, of whom 324 (49%) were children aged <15 years. The age‐standardised incidence rate was 4.46 (95% confidence interval [CI] 3.99–4.98) per million children and 1.06 (95% CI 0.94–1.18) per million adults aged ≥15 years. Prevalence of LCH was 9.95 (95% CI 9.14–10.81) per million persons at the end of 2019. The 1‐year overall survival (OS) was 99% (95% CI 97%–100%) for children and 90% (95% CI 87%–93%) for adults. Those aged ≥60 years had poorer OS than those aged <15 years (hazard ratio [HR] 22.12, 95% CI 7.10–68.94; p < 0.001). People in deprived areas had lower OS than those in the least deprived areas (HR 5.36, 95% CI 1.16–24.87; p = 0.03). There will inevitably be other environmental factors and associations yet to be identified, and the continued standardised data collection will allow further evaluation of data over time. This will be increasingly important with developments in LCH management following the large collaborative international trials such as LCH IV. John Wiley and Sons Inc. 2022-09-19 2022-12 /pmc/articles/PMC9826274/ /pubmed/36122574 http://dx.doi.org/10.1111/bjh.18459 Text en © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Haematological Malignancy‐clinical Liu, Hanhua Stiller, Charles A. Crooks, Colin J. Rous, Brian Bythell, Mary Broggio, John Rankin, Judith Nanduri, Vasanta Lanyon, Peter Card, Tim R. Ban, Lu Elliss‐Brookes, Lucy Broughan, Jennifer M. Paley, Lizz Wong, Kwok Bacon, Andrew Bishton, Mark West, Joe Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title | Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title_full | Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title_fullStr | Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title_full_unstemmed | Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title_short | Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 |
title_sort | incidence, prevalence and survival in patients with langerhans cell histiocytosis: a national registry study from england, 2013–2019 |
topic | Haematological Malignancy‐clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826274/ https://www.ncbi.nlm.nih.gov/pubmed/36122574 http://dx.doi.org/10.1111/bjh.18459 |
work_keys_str_mv | AT liuhanhua incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT stillercharlesa incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT crookscolinj incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT rousbrian incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT bythellmary incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT broggiojohn incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT rankinjudith incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT nandurivasanta incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT lanyonpeter incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT cardtimr incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT banlu incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT ellissbrookeslucy incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT broughanjenniferm incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT paleylizz incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT wongkwok incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT baconandrew incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT bishtonmark incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 AT westjoe incidenceprevalenceandsurvivalinpatientswithlangerhanscellhistiocytosisanationalregistrystudyfromengland20132019 |